Has Ashish Gupta, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,170,079 in general payments to Ashish Gupta, MD across 2,398 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ashish Gupta, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ashish Gupta, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ashish Gupta, MD

Cardiovascular Disease · Phoenix, AZNPI 1982782470

Payments from drug & device makers

$1,170,079in general payments, 2019–2025

Across 2,398 payments — averaging $487.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Actelion Pharmaceuticals US, Inc.$477K
Bayer$202K
Boston Scientific$178K
Impulse Dynamics (USA) Inc.$118K
Merck$67K
Janssen Research & Development, LLC$36K
plus $93K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Actelion Pharmaceuticals US, Inc.	716	$476,742
Bayer	270	$202,056
Boston Scientific	267	$178,029
Impulse Dynamics (USA) Inc.	188	$118,131
Merck	107	$66,588
Janssen Research & Development, LLC	11	$35,750
Abbott	185	$20,883
Actelion Pharmaceuticals, Ltd	5	$19,850
Cvrx, Inc.	32	$11,197
Medtronic(3 entities)	80	$7,760
Penumbra, Inc.	32	$5,608
Atricure, Inc.	19	$3,791
United Therapeutics Corporation	12	$3,725
Inari Medical, Inc.	22	$2,454
Philips North America LLC	20	$2,023
Novartis	86	$1,562
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	30	$1,384
Amgen	61	$1,096
Biosense Webster, Inc.	8	$926
AstraZeneca	16	$897
Heartflow, Inc.	8	$893
Edwards Lifesciences	10	$840
Regeneron Healthcare Solutions, Inc.	13	$794
Cardiva Medical, Inc.	12	$735
Johnson & Johnson(2 entities)	44	$685
Sanofi-aventis U.S. LLC	9	$613
Novo Nordisk	13	$579
Amarin Pharma, Inc.	10	$470
Tactile Systems Technology Inc	11	$346
E.r. Squibb & Sons, L.L.C.	20	$333
Itamar Medical Inc	3	$306
Inspire Medical Systems, Inc.	2	$278
Regeneron	2	$253
Pfizer	13	$250
Ensodata, Inc.	2	$247
Alnylam Pharmaceuticals Inc.	7	$225
Esperion Therapeutics, Inc.	7	$208
Kestra Medical Technology Services, Inc.	8	$202
Janssen Scientific Affairs, LLC	2	$184
Biotronik Inc.	2	$155
Abiomed	5	$126
Acutus Medical, Inc.	1	$126
Sandoz	4	$107
Endologix LLC	1	$100
ZOLL Respicardia, Inc.	1	$97
Travere Therapeutics, Inc.	1	$75
Silk Road Medical, Inc.	1	$52
Inspiremd Ltd	1	$51
Bardy Diagnostics, Inc.	3	$45
Astellas Pharma US Inc	2	$43
Kowa Pharmaceuticals America, Inc.	3	$39
Kiniksa Pharmaceuticals International, PLC	2	$33
Chiesi USA, Inc.	2	$30
Boehringer Ingelheim	2	$29
Endotronix, Inc.	1	$24
Beone Medicines USA, Inc.	1	$20
Amryt Pharma Holdings Ltd	1	$18
CSL Behring	1	$16

How this compares

$1,170,079 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona →

Medicare billing

Part B allowed, 2024

$560,488

Medicare patients

1,175

Services billed

6,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Phoenix

Rajkumar SugumaranPhoenix$957K
Robert ScottPhoenix$331K
Julie RosenthalPhoenix$313K
Tabitha MoePhoenix$256K
Mehrdad SaririanPhoenix$158K
Jesse SethiPhoenix$150K
Adam SabbathPhoenix$109K
Venkataramanan GangadharanPhoenix$97K
Namit RohantPhoenix$83K
Nathan LauferPhoenix$81K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →